Bhupender Sharma

Bhupender Sharma

Auto-generated profile, based on publicly available information

Bhupender Sharma

Center of Emphasis in Neuroscience Department of Molecular and Translational Medicine Paul L. Foster School of Medicine Texas Tech University Health Sciences Center El Paso El Paso Texas USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2025 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
Subodh KumarSubodh Kumar
Subodh Kumar
Enrique RamosEnrique Ramos
Enrique Ramos
AHAxel Hidalgo
Axel Hidalgo
DRDaniela Rodarte
Daniela Rodarte
BSBhupender Sharma
Bhupender Sharma
SGShrikanth Gadad
Shrikanth Gadad
Synapse dysfunction is an early event in Alzheimer’s disease (AD) caused by various factors, including amyloid beta, p-tau, inflammation, and aging. However, the precise molecular mechanism underlying synapse dysfunction in AD remains largely unknown. To understand this, we comprehensively analyzed the synaptosomes fraction in post-mortem brain samples from AD patients and cognitively normal individuals. We conducted high-throughput transcriptomic analyses to identify changes in microRNA (miRNA) and mRNA levels in synaptosomes extracted from the brains of unaffected individuals and those with AD. Additionally, we performed mass spectrometry analysis of synaptosomal proteins in the same sample group. These analyses revealed significant differences in the levels of miRNAs, mRNAs, and proteins between the two groups. To gain further insights into the pathways or molecules involved, we employed an integrated omics approach to study the molecular interactions of deregulated synapse miRNAs, mRNAs, and proteins in samples from individuals with AD and the control group, demonstrating the impact of deregulated miRNAs on their target mRNAs and proteins. Furthermore, the DIABLO analysis revealed complex relationships among mRNAs, miRNAs, and proteins that could be key in understanding the pathophysiology of AD. Our study identified novel synapse-associated candidates that could be critical in restoring synapse dysfunction in AD.

9 July 2025 in Clinical and Translational Medicine
Verified
Journal Article
Open access
Davin DevaraDavin Devara
Davin Devara
BSBhupender Sharma
Bhupender Sharma
GGGunjan Goyal
Gunjan Goyal
DRDaniela Rodarte
Daniela Rodarte
AKAditi Kulkarni
Aditi Kulkarni
Subodh KumarSubodh Kumar
Subodh Kumar
Introduction: Alzheimer's disease (AD) lacks a less invasive and early detectable biomarker. Here, we investigated the biomarker potential of miR‐501‐3p and miR‐502‐3p using different AD sources.Methods: MiR‐501‐3p and miR‐502‐3p expressions were evaluated in AD cerebrospinal fluid (CSF) exosomes, serum exosomes, familial and sporadic AD fibroblasts and B‐lymphocytes by qRT‐PCR analysis. Further, miR‐501‐3p and miR‐502‐3p expressions were analysed in APP, Tau plasmid transfected cells media exosomes and in different brain cell types.Results: MiR‐501‐3p and miR‐502‐3p expressions were significantly up‐regulated in AD CSF exosomes relative to controls. MiRNA levels were high in accordance with amyloid plaque and NFT density in multiple brain regions. Similarly, both miRNAs were elevated in AD and MCI serum exosomes compared with controls. MiR‐502‐3p expression was high in familial AD and sporadic AD B‐lymphocytes. MiR‐501‐3p and miR‐502‐3p expression were elevated intracellularly and secreted extracellularly in response to APP and Tau pathology. Finally, neurons and astrocytes displayed high expression of these miRNAs.Discussion: These results suggest that miR‐501‐3p and miR‐502‐3p could be promising biomarkers for AD.Key points: MiR‐501‐3p and miR‐502‐3p expression is elevated in AD CSF exosomes, AD serum exosomes, AD B‐lymphocytes and Aβ‐ and Tau‐treated cells. MiR‐501‐3p and miR‐502‐3p are correlated with amyloid plaque and NFT tangle density in specific brain regions. MiR‐501‐3p and miR‐502‐3p are highly expressed in neurons and astrocytes, suggesting that these cells are the source of miRNA secretion. MiR‐501‐3p and miR‐502‐3p could be a promising biomarker panel for AD

2 February 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
JRJaime Ramirez-Gomez
Jaime Ramirez-Gomez
SDSarthak Dalal
Sarthak Dalal
Davin DevaraDavin Devara
Davin Devara
BSBhupender Sharma
Bhupender Sharma
DRDaniela Rodarte
Daniela Rodarte
Subodh KumarSubodh Kumar
Subodh Kumar
Alzheimer's disease (AD) is a chronic neurodegenerative disorder that is characterized by memory and physical impairment in aged individuals. microRNAs (miRNAs) are small, single-stranded noncoding RNAs that induce translational repression by binding to the 3’ UTR of a target mRNA. miRNAs play a crucial role in neurological activity by mediating cellular proliferation, synaptic plasticity, apoptosis and more. Ongoing research in patents and clinical trials have called attention to promising miRNAs as biomarkers and therapeutics in AD. Recent research has shown that miRNAs are aberrantly expressed in AD brain, blood, cerebrospinal fluid and serum. Attenuated miRNA expressions have diagnostic potential in AD by interacting with amyloid-β synthesis, phosphorylated tau, and neurofibrillary tangles. In this study, miRNA-29a, miRNA-125b, miRNA-34a, miRNA-146a, and miRNA-155 have shown promise as potential biomarker candidates for AD. Improving cognitive symptoms can be traced to restoring the endogenous miRNA activity by synthesizing miRNA mimics and miRNA antisense oligonucleotides. miRNA-483-5p, miRNA-188-5p, miRNA-219, miRNA135a/5p, miRNA-23/23b-3p, miRNA-124, and miRNA-455-3p are growing therapeutics for AD. However, miRNA-based therapeutics struggle outside of preclinical testing. miRNA-107, miRNA-206, miRNA-30/7, and miRNA-142-3p face bottlenecks in clinical trials due to a lack of experimental design, transparency and volunteer size. Patenting recent miRNA-based developments demonstrates the commitment in identifying a new biomarker and/or therapeutic for AD.

23 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
BSBhupender Sharma
Bhupender Sharma
SJShaveta Jain
Shaveta Jain
LSLakhwinder Singh
Lakhwinder Singh
SSShruti Sharma
Shruti Sharma
RKRaman Kaur
Raman Kaur
ACAnuradha Chakraborti
Anuradha Chakraborti
The focus of this study is on Rheumatic heart disease (RHD), an autoimmune consequence of rheumatic fever leading to mitral valve damage. Aim is to explore the role of exosomes derived from RHD patients in promoting angiogenesis during RHD pathogenesis. Exosomes were isolated via column chromatography from the pericardial fluid (PF) and serum of RHD patients, pericardial fluid from non-RHD patients undergoing coronary artery bypass grafting (CABG) surgery, and serum of healthy individuals. These exosomes were characterized by transmission electron microscopy (TEM) and western blotting. Human umbilical vein endothelial cells (HUVECs) cultured from umbilical cord(s), were treated with purified exosomes from RHD, CABG patients or healthy individuals. Exosome treatment induced morphological changes in HUVECs, including elongation and tube-like structure formation. The qRT-PCR gene expression analysis revealed significant upregulation of angiogenic markers (VEGF-A 2.7-fold, MMP2 1.5-fold) and inflammatory cytokine (IL-4 15.17-fold), in HUVECs stimulated with RHD serum exosomes. Conversely, there was downregulation of anti- angiogenic genes (RASA-1 0.65-fold and endostatin 0.4-fold). Notably, elevated levels of miR- 150-5p (34.29 + 9.524-fold mean difference; p= 0.0007) were detected in serum-derived exosomes from RHD patients compared to healthy controls. Stimulation of HUVECs with RHD serum exosomes resulted in reduction in the expression of TP53 (0.227-fold; p= 0.006), a known target of miR-150-5p. Furthermore, transfection of HUVECs with miR-150-5p mimics induced the formation of angiogenic endothelial tubes, underscoring the role of miR-150-5p in promoting angiogenesis. Graphical